Vingender Szonja, Dőri Ferenc, Schmidt Péter, Hermann Péter, Vaszilkó Mihály Tamás
Semmelweis University, Department of Oro-Maxillofacial Surgery and Stomatology, 1085, Budapest, Maria St. 52, Hungary.
Semmelweis University, Department of Periodontology, 1085, Budapest, Szentkiralyi St. 47, Hungary.
J Craniomaxillofac Surg. 2023 Jan;51(1):1-6. doi: 10.1016/j.jcms.2023.01.017. Epub 2023 Jan 28.
This study aimed to evaluate the clinical effects of hyaluronic acid (HA), platelet-rich plasma (PRP), and platelet-rich fibrin (I-PRF) injections in the internal derangement of the temporomandibular joint. Adult patients who had failed to respond to nonsurgical treatment were were included in the study. The patients were divided into three treatment groups according to the given substance: 1) HA administration three times in a row on a weekly basis, 2) a single dose of PRP, or 3) a single dose of I-PRF. Clinical assessment was performed preoperatively and 6 and 12 months after the treatment, including maximal mouth opening (MMO) and pain level (Visual Analog Scale). Low and high molecular weight (HA, HA) hyaluronic acid forms were also compared. 68 adult patients, with a total of 109 joints were included in the study. The mean age was 53 ± 16 years. The statistical analysis showed a significant improvement in MMO in the HA group (p < 0.01). The pain level significantly decreased in all treatment groups (p<0.01). Comparing HA and HA forms, no significant difference was found in the evaluation of MMO and VAS values. Within the limitations of the study it seems that due to the similar effects of HA and the autologous blood substances, the platelet concentrates should be preferred in the intra-articular treatment in order to reduce the risk of possible adverse effects.
本研究旨在评估透明质酸(HA)、富血小板血浆(PRP)和富血小板纤维蛋白(I-PRF)注射治疗颞下颌关节内紊乱的临床效果。纳入对非手术治疗无反应的成年患者。根据给予的物质将患者分为三个治疗组:1)每周连续三次给予HA,2)单次给予PRP,或3)单次给予I-PRF。在术前以及治疗后6个月和12个月进行临床评估,包括最大开口度(MMO)和疼痛程度(视觉模拟评分)。还比较了低分子量和高分子量(HA,HA)透明质酸形式。本研究共纳入68例成年患者,共109个关节。平均年龄为53±16岁。统计分析显示HA组的MMO有显著改善(p<0.01)。所有治疗组的疼痛程度均显著降低(p<0.01)。比较HA和HA形式,在MMO和VAS值评估中未发现显著差异。在本研究的局限性内,由于HA和自体血物质的效果相似,为降低可能的不良反应风险,关节内治疗应首选血小板浓缩物。